Matthew J Fuchter

Affiliations: 
Chemistry Imperial College London, London, England, United Kingdom 
Google:
"Matthew Fuchter"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rushworth JL, Montgomery KS, Cao B, et al. (2020) Glycosylated Nanoparticles Derived from RAFT Polymerization for Effective Drug Delivery to Macrophages. Acs Applied Bio Materials. 3: 5775-5786
Fuchter MJ. (2020) On the Promise of Photopharmacology Using Photoswitches: A Medicinal Chemist's Perspective. Journal of Medicinal Chemistry
Bardell-Cox OA, White AJP, Aragón L, et al. (2019) Synthetic studies on the reverse antibiotic natural products, the nybomycins. Medchemcomm. 10: 1438-1444
Rueda-Zubiaurre A, Yahiya S, Fischer O, et al. (2019) Structure-activity relationship studies of a novel class of transmission blocking antimalarials targeting male gametes. Journal of Medicinal Chemistry
Delves MJ, Miguel-Blanco C, Matthews H, et al. (2018) A high throughput screen for next-generation leads targeting malaria parasite transmission. Nature Communications. 9: 3805
Chavas TEJ, Fuchter MJ, DiMaggio PA. (2018) Unbiased Mass Spectrometry Elucidation of the Targets and Mechanisms of Activity-Based Probes: A Case Study involving Sulfonyl Fluorides. Acs Chemical Biology
Patel H, Periyasamy M, Sava GP, et al. (2018) ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics
Lubin AS, Zubiaurre AR, Matthews H, et al. (2018) Development of a Photo-crosslinkable Diaminoquinazoline Inhibitor for Target Identification in Plasmodium Falciparum. Acs Infectious Diseases
Hazel P, Kroll SHB, Bondke A, et al. (2018) Corrigendum: Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. Chemmedchem. 13: 207
Ali S, Patel H, Periyasamy M, et al. (2018) Abstract P1-10-05: ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of estrogen receptor positive and negative breast cancer Cancer Research. 78
See more...